Program
florbetaben f-18
Also written as “Florbetaben (BAY94-9172)”, “[18F]florbetaben” and “Florbetaben F18”.
Its studies are mostly in Alzheimer Disease · Amyloid Neuropathies, Familial · Down Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lantheus | 70 open or running | phase 4since Feb 4, 2016 | Sep 9, 2008 | none ahead |
| Sinotau Pharmaceutical Group | 10 open or running | no phasesince Aug 8, 2022 | Aug 8, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2008First study: phase 2 study in Alzheimer DiseaseNew to LantheusLantheus · NCT00750282 · 422 enrolled · United States, Australia, Germany and more
- Jun 24, 2009Phase 2 study in Down SyndromeLantheus · NCT00928304 · 109 enrolled · United States
- Nov 16, 2009Phase 3 study in Alzheimer DiseaseLantheus · NCT01020838 · 218 enrolled · United States, Australia, France and more
- Apr 1, 2010Phase 1 study in Alzheimer DiseaseLantheus · NCT01138111 · 45 enrolled · Australia
- Feb 4, 2016Phase 4 study in Alzheimer DiseaseLantheus · NCT02681172 · 218 enrolled · France
- Jan 6, 2022Phase 3 study in Amyloid Neuropathies, FamilialLantheus · NCT05184088 · 244 enrolled · United States, Germany, Spain and more
- Aug 8, 2022Sinotau Pharmaceutical Group’s first study: no phase study in Alzheimer DiseaseNew to Sinotau Pharmaceutical GroupSinotau Pharmaceutical Group · NCT05527288 · 50 enrolled · China
- Dec 19, 2024Phase 1 study in Amyloid Neuropathies, FamilialLantheus · NCT06790394 · 15 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06790394Amyloid Neuropathies, Familial · United Kingdom | 1 | Completed | Lantheus | Oct 7, 2026 | 15 |
| NCT05527288Alzheimer Disease · China | – | Completed | Sinotau Pharmaceutical Group | Sep 12, 2021 | 50 |
| NCT05184088Amyloid Neuropathies, Familial · United States, Germany, Spain and more | 3 | Completed | Lantheus | Apr 21, 2026 | 244 |
| NCT02681172Alzheimer Disease · France | 4 | Completed | Lantheus | Sep 2016 | 218 |
| NCT01138111Alzheimer Disease · Australia | 1 | Completed | Lantheus | Dec 2011 | 45 |
| NCT01020838Alzheimer Disease · United States, Australia, France and more | 3 | Completed | Lantheus | Sep 2011 | 218 |
| NCT00928304Down Syndrome · United States | 2 | Completed | Lantheus | Jan 2011 | 109 |
| NCT00750282Alzheimer Disease · United States, Australia, Germany and more | 2 | Completed | Lantheus | Nov 2010 | 422 |
How it is read
Names in the registry
- “Florbetaben (BAY94-9172)”, 4 entries
- “[18F]florbetaben”, 1 entry
- “Florbetaben F18”, 1 entry
- “Neuraceq (florbetaben 18F)”, 1 entry
- “Drug: [18F]florbetaben”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 5 studies
- Amyloid Neuropathies, Familial, 2 studies
- Down Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.